InSightec was founded in 1999 when GE Healthcare (then GE Medical Systems) and Elbit Medical Imaging transferred their proprietary technology to the company to enable it to concentrate on developing the promising MR guided focused ultrasound surgery both companies had investigated. Since then, InSightec has invested over $100 million in research and development. The company holds over 30 patents with additional intellectual property pending.
InSightec developed ExAblate® 2000– a product that integrates focused ultrasound energy and Magnetic Resonance Imaging (MRI) to provide a non-invasive treatment modality that can replace invasive procedures and provide therapeutic alternatives. ExAblate was approved by the U.S. Food and Drug Administration (FDA) in October 2004 to treat symptomatic uterine fibroids and to date over 8000 women has been treated worldwide for symptomatic uterine fibroids. InSightec is conducting clinical trials in oncology indications: pain palliation of bone metastases, breast cancer, prostate, brain applications, liver tumours and Fertility Enhancement trial. ExAblate also received the European CE mark for treating pain palliation caused by bone metastases.
InSightec developped ExAblate Neuro which is designed to utilize the core MRgFUS technology for brain applications. It is THE ONLY system in the world developed and clinically used (CE mark approved) for brain treatment using MRgFUS.

Key staff:

Dr. Yoav Levy: R&D manager for liver program. Dr, Levy received his PhD. in Biomedical Engineering from the Technion Israel Institute of Technology for his work on “Investigation of New Techniques for Ultrasonic Imaging”


This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no 611889